7月12日到19日，全球共签署了13项资产授权与合作交易。中国医药市场交易活跃，共达成8项交易，包括5项出海交易、1项引进交易和2项国内交易。其中值得关注的交易是辐联科技向韩国SK Biopharma授权一临床前资产，总价值5.715亿美元；以及澳宗生物与华东医药就III期资产TTYP01达成交易，总价值1.816亿美元。
国际市场上，共签署了5项资产授权和合作交易。本周的亮点是Orum Therapeutics与Vertex Pharmaceuticals就前者的双精度靶向蛋白降解（TPD²）技术平台达成的授权和选择权协议，预付款1500万美元，总价值9.45亿美元。
From July 12 to 19, a total of 13 licensing deals were signed globally, marking a fruitful week for the China Biotech Industry. Of these, 8 licensing and cooperation agreements were sealed within China. The deals included 5 out-licensing agreements, 1 in-licensing deal, and 2 domestic agreements. The notable deals are Full-Life Technologies and SK Biopharma entered into an out-licensing agreement worth $571.5 million for a pre-clinical stage asset and Auzone Biological and Huadong Medicine agreed to a $181.6 million deal for the Phase III asset, TTYP01.
Globally, a total of 5 licensing and cooperation deals were signed. The highlight of the week was the licensing and option deal between Orum Therapeutics and Vertex Pharmaceuticals for dual-precision targeted protein degradation (TPD²) platform, with an upfront payment of $15 million and totaling $945 million.
2b. Global section
3. M&A Deals
4. Top Deals of the year 2024
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions. For more information, please visit www.yafocapital.com
Event Name:
